TCV 295

Drug Profile

TCV 295

Latest Information Update: 13 Oct 2000

Price : $50

At a glance

  • Originator Takeda
  • Class Antihypertensives; Vasodilators
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertension; Ischaemic heart disorders

Most Recent Events

  • 13 Oct 2000 Discontinued-Preclinical for Hypertension in Japan (IV)
  • 13 Oct 2000 Discontinued-Preclinical for Ischaemic heart disorders in Japan (Unknown route)
  • 12 Jun 2000 Profile reviewed but no significant modifications made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top